Abstract: N6-methyladenosine RNA (m6A) is the most abundant type of post-transcriptional modification in eukaryotic cells. Various RNA types, such as messenger RNA (mRNA), long non-coding RNA (lncRNA), circular RNA (circRNA), microRNA (miRNA) and transfer RNA (tRNA), can undergo m6A methylation modifications. Recently, aberrant m6A methylation modifications have been found to be the trigger of renal fibrosis in kidney diseases, which can promote or inhibit interstitial fibrosis through different targets and signaling pathways, but the exact mechanism needs further investigation. This paper aimed to review the mechanism of m6A methylation modification in renal fibrosis and provide new ideas for the development of new clinical drugs.